| 1 |
22486291 | [Guidelines for alemtuzumab treatment in chronic lymphocytic leukaemia (CLL)]. | 2012 Mar |
1 |
| 2 |
21670470 | Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. | 2011 Aug 25 |
1 |
| 3 |
19895616 | Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). | 2010 Feb |
1 |
| 4 |
21030349 | Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia. | 2010 Oct |
1 |
| 5 |
18682948 | Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. | 2009 Feb |
1 |
| 6 |
18225973 | Mycobacterium avium complex infection after alemtuzumab therapy for chronic lymphocytic leukemia. | 2008 Feb |
1 |
| 7 |
17960607 | Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies. | 2007 Dec 1 |
1 |
| 8 |
15858611 | Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia. | 2005 Jul |
1 |
| 9 |
15910809 | Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. | 2005 May 9 |
1 |
| 10 |
12512923 | Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia. | 2002 |
1 |